C4b-binding protein (C4BP) Inhibits development of experimental arthritis in mice

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 136-142

  Blom, A M ^a,b   Nandakumar, K S ^b,c   Holmdahl, R ^b,c  

^a Malmö University Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; COLLAGEN ANTIBODY; COMPLEMENT COMPONENT C4B BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; CIRCULATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THERAPY EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; COMPLEMENT C4B; COMPLEMENT C4B-BINDING PROTEIN; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; MALE; MICE; MICE, MUTANT STRAINS;

EID: 58349122882     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.085753     Document Type: Article

References (41)

1. Riedemann NC. Ward PA. Complement in ischemia reperfusion injury. Am J Pathol 2003; 162:363-7.
2. Blom AM, Villoutreix BO, Dahlback B. Functions of human complement inhibitor C4bbinding protein in relation to its structure. Arch Immunol Ther Exp (Warsz) 2004; 52:83-95.
3. Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma protein C4b binding and C3b inactivator. Proc Natl Acad Sci USA 1979; 76:6596-600.
4. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V. Human C4b-binding protein, isolation and characterization. J Exp Med 1978; 148:207-22.
5. Blom AM, Kask L, Dahlback B. CCP1-4 of the C4b-binding protein a-chain are required for Factor I mediated cleavage of C3b. Mol Immunol 2003; 39:547-56.
6. Trouw LA, Nilsson SC, Goncalves I, Landberg G, Blom AM. C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med 2005; 201:1937-48.
7. Sjöberg A. Önnerfjord P, Morgelin M, Heinegård D, Blom AM. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem 2005; 280:32301-8.
8. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990; 49:747-52.
9. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1531-7.
10. Corvetta A, Pomponio G. Rinaldi N, Luchetti MM, Di Loreto C, Stramazzotti D. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol 1992; 10:433-8.
11. Moxley G, Ruddy S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 1985; 28:1089-95.
12. Del Nagro CJ, Kolla RV, Rickert RC. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J Immunol 2005; 175:5379-89.
13. Morgan K, Clague RB, Shaw MJ, Firth SA, Twose TM, Holt PJ. Native type II collagen-induced arthritis in the rat: the effect of complement depletion by cobra venom factor. Arthritis Rheum 1981; 24:1356-62.
14. Watson WC, Brown PS, Pitcock JA, Townes AS. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57BI/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum 1987; 30:460-5.
15. Mori L. de Libero G. Genetic control of susceptibility to collagen-induced arthritis in T cell receptor β-chain transgenic mice. Arthritis Rheum 1998; 41:256-62.
16. Mclndoe RA, Bohlman B, Chi E, Schuster E, Lindhardt M, Hood L. Localization of non-Mhc collagen-induced arthritis susceptibility loci in DBA/1j mice. Proc Natl Acad Sci USA 1999; 96:2210-4.
17. Johansson AC, Sundler M, Kjellen P, Johannesson M, Cook A, Lindqvist AK. et al. Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcγRllb and is not associated with loci controlling diabetes. Eur J Immunol 2001; 31:1847-56.
18. Lindqvist AK, Johannesson M, Johansson AC, Nandakumar KS, Blom AM, Holmdahl R. Backcross and partial advanced intercross analysis of nonobese diabetic genemediated effects on collagen-induced arthritis reveals an interactive effect by two major loci. J Immunol 2006; 177:3952-9.
19. Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N, et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 2002; 196:1461-71.
20. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol 2007; 179:4101-9.
21. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 2004; 34:1208-16.
22. Nandakumar KS, Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 2006: 8:223.
23. Nandakumar KS, Andren M, Martinsson P, Bajtner E, Hellstrom S, Holmdahl R, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB. Eur J Immunol 2003; 33:2269-77.
24. Nandakumar KS, Backlund J, Vestberg M, Holmdahl R. Collagen type II (C11)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by Cll-reactive T cells. Arthritis Res Ther 2004; 6:R544-50.
25. Nandakumar KS, Svensson L, Holmdahl R. Collagen type ll-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003; 163:1827-37.
26. Blom AM, Kask L, Dahlbäck B. Structural requirements for the complement regulatory activities of C4BP. J Biol Chem 2001; 276:27136-44.
27. Marcovina SM, Zoppo A, Vigano-D'Angelo S, Di Cola G, D'Angelo A. Determination of serum levels of complement componenet C4b-binding protein: influence of age and inflammation. Int J Clin Lab Res 1991; 21:171-5.
28. Holmdahl R, Jansson L, Gullberg D, Rubin K, Forsberg PO, Klareskog L. Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin Exp Immunol 1985; 62:639-46.
29. Holmdahl R, Klareskog L, Andersson M, Hansen C. High antibody response to autologous type II collagen is restricted to H-2q. Immunogenetics 1986; 24:84-9.
30. Nandakumar KS, Holmdahl R. Arthritis induced with cartilage-specific antibodies is IL-4-dependent. Eur J Immunol 2006; 36:1608-18.
31. Backlund J, Nandakumar KS, Bockermann R, Mori L, Holmdahl R. Genetic control of tolerance to type II collagen and development of arthritis in an autologous collageninduced arthritis model. J Immunol 2003; 171:3493-9.
32. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, et al. Blockade of antibody-induced glomerulonephritis with Crry-lg, a soluble murine complement inhibitor. J Immunol 1998; 160:4553-60.
33. Kask L, Trouw L, Dahlbäck B, Blom AM. C4b-binding protein-protein S complex inhibits phagocytosis of apoptotic cells. J Biol Chem 2004; 279:23869-73.
34. Brodeur S, Angelini F, Bacharier LB, Blom AM, Mizoguchi E, Fujiwara H, et al. C4bbinding protein (C4BP) activates B cells through the CD40 Receptor. Immunity 2003; 18:837-48.
35. Williams KT, Young SP, Negus A, Young LS, Adams DH, Afford SC. C4b binding protein binds to CD154 preventing CD40 mediated cholangiocyte apoptosis: a novel link between complement and epithelial cell survival. PLoS ONE 2007v; 2:e159.
36. Trouw LA, Bengtsson AA, Gelderman KA, Dahlbäck B, Sturfelt G, Blom AM. C4bbinding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007; 282:28540-8.
37. Sjoberg AP, Trouw LA, McGrath FD, Hack CE, Blom AM. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol 2006; 176:7612-20.
38. Dreja H, Annenkov A, Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum 2000; 43:1698-709.
39. Banda NK, Kraus D, Vondracek A, Huynh LH, Bendele A, Holers VM, et al. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 2002, 46:3065-75.
40. Harris CL, Williams AS, Linton SM, Morgan BP. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol 2002; 129:198-207.
41. Wang Y. Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92:8955-9.